Ticagrelor Plus Aspirin for Stroke or TIA of Atherosclerotic Origin

A preplanned exploratory analysis suggests a benefit in this patient subgroup.

Ticagrelor is a reversible platelet P2Y₁₂ receptor inhibitor. The recently completed THALES trial, comparing aspirin plus ticagrelor (A+T) versus aspirin alone in patients with high-risk transient ischemic attack (TIA) or mild stroke, found a 17% reduction in stroke or death within 30 days in the overall trial population. Whether the A+T combination is more effective in certain stroke subtypes has not been explored. In a preplanned exploratory analysis, the authors have now compared treatments effects in THALES trial participants with likely atherosclerotic stroke (≥30% of an intracranial or extracranial artery linked with clinical symptoms) and in participants with stroke of other mechanisms. Patients were enrolled within 24 hours. The tic…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Ticagrelor Plus Aspirin for Stroke or TIA of Atherosclerotic Origin

Topics

Reviewing Author